Analysis, Cantargia: Second half in CANFOUR study
25 Mar 2019
The phase IIa part of the CANFOUR study with cancer antibody treatment nidanilimab has been initiated. A directed share issue enables further extension of investigations. We raise fair value on the back of advances in the pipeline.
Read the full report (Swedish) here.